DPP4活性、高胰岛素血症与动脉粥样硬化
本综述基于PubMed检索,汇总DPP4与高胰岛素血症在动脉粥样硬化中的作用证据:胰岛素抵抗下高胰岛素血症促血管炎症与动脉粥样硬化,DPP4活性在肥胖人群升高并模拟其致动脉粥样作用;临床前DPP4抑制改善内皮功能、减少动脉粥样硬化,小型临床研究示颈动脉内膜增厚减少、内皮功能改善和动脉僵硬度降低,但未转化为2型糖尿病心血管风险降低。
要点
- 胰岛素抵抗相关高胰岛素血症通过血管炎症、平滑肌细胞生长等促进动脉粥样硬化。
- 肥胖人群DPP4活性升高,DPP4可能连接中心性肥胖、胰岛素抵抗与动脉粥样硬化。
- DPP4抑制剂在临床前和小型临床研究显示血管益处,但未转化为2型糖尿病心血管风险降低。
核心结论
- DPP4可能是中心性肥胖、胰岛素抵抗与动脉粥样硬化之间的关键联系。
- DPP4功能的知识缺口及临床前与大规模随机对照研究中DPP4抑制剂心血管结局的差异值得进一步研究。
研究设计与样本
- 综述类:通过PubMed检索「insulin and atherosclerosis」「hyperinsulinemia」「atherosclerosis」或「cardiovascular outcomes」并与「DPP4」交叉检索,纳入相关研究与综述文章。
主要发现
- 胰岛素抵抗状态下高胰岛素血症促进血管炎症、血管平滑肌细胞生长、病理性胆固醇谱、高血压及免疫细胞募集至内皮,均促进动脉粥样硬化。
- DPP4具有多效功能,在肥胖人群中人DPP4活性升高,并在胰岛素抵抗状态下模拟高胰岛素血症的致动脉粥样硬化作用。
- 遗传性DPP4缺失保护啮齿类动物免于发生胰岛素抵抗并改善心血管结局。
- 在促动脉粥样硬化临床前模型中抑制DPP4可减少炎症和氧化应激、改善内皮功能并减少动脉粥样硬化,升高的肠促胰岛素水平可能部分但非完全解释这些获益。
- 使用DPP4抑制剂的小型临床研究显示颈动脉内膜增厚减少、内皮功能改善和动脉僵硬度降低,但尚未转化为有既往或极高心血管疾病风险的2型糖尿病个体的心血管风险降低。
临床怎么用
- 内分泌科医生应认识到高胰岛素血症和DPP4活性升高是肥胖与胰岛素抵抗人群的促动脉粥样硬化因素。
- DPP4抑制剂在临床前和小型临床研究显示血管益处,但现有证据未支持其用于2型糖尿病心血管风险降低。
局限性
- DPP4功能存在知识缺口。
- 临床前与大规模随机对照研究中DPP4抑制剂的心血管结局存在差异。
- 小型临床研究的血管获益尚未转化为2型糖尿病个体的心血管风险降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Obesity and type 2 diabetes are associated with chronic hyperinsulinemia, elevated plasma levels of dipeptidyl peptidase-4 (DPP4), and a pro-atherosclerotic milieu. EVIDENCE ACQUISITION: PubMed search of the term "insulin and atherosclerosis," "hyperinsulinemia," "atherosclerosis," or "cardiovascular outcomes" cross-referenced with "DPP4." Relevant research and review articles were reviewed. EVIDENCE SYNTHESIS: Hyperinsulinemia in the setting of insulin resistance promotes vascular inflammation, vascular smooth muscle cell growth, pathological cholesterol profile, hypertension, and recruitment of immune cells to the endothelium, all contributing to atherosclerosis. DPP4 has pleiotropic functions and its activity is elevated in obese humans. DPP4 mirrors hyperinsulinemia's atherogenic actions in the insulin resistant state, and genetic deletion of DPP4 protects rodents from developing insulin resistance and improves cardiovascular outcomes. DPP4 inhibition in pro-atherosclerotic preclinical models results in reduced inflammation and oxidative stress, improved endothelial function, and decreased atherosclerosis. Increased incretin levels may have contributed to but do not completely account for these benefits. Small clinical studies with DPP4 inhibitors demonstrate reduced carotid intimal thickening, improved endothelial function, and reduced arterial stiffness. To date, this has not been translated to cardiovascular risk reduction for individuals with type 2 diabetes with prior or exaggerated risk of cardiovascular disease. CONCLUSION: DPP4 may represent a key link between central obesity, insulin resistance, and atherosclerosis. The gaps in knowledge in DPP4 function and discrepancy in cardiovascular outcomes observed in preclinical and large-scale randomized controlled studies with DPP4 inhibitors warrant additional research.
引用
- Love KM, Liu Z. DPP4 Activity, Hyperinsulinemia, and Atherosclerosis. J Clin Endocrinol Metab. 2021. PMID: 33570554. doi:10.1210/clinem/dgab078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。